The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

Bristol-Myers Squibb (BMY) to announce Q4 earnings on February 6th. Analysts expect $1.47 EPS on $11.56B revenue.

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,611 calls trading, 2.0x expected, and implied vol increasing over 1 point to 29.73%. May-25 67.5 calls and Aug-25 45 puts are the ...

Looking at Bristol-Myers Squibb Company's (NYSE:BMY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...